A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Key Points

• Findings suggest that oral lisavanbulin may have a role in treating high-grade glioma and glioblastoma.
• Key biomarker assessments provide insights into the drug’s mechanism and its suitability for patients with these tumors.
• Phase 1/2a dose-finding study evaluates safety and effectiveness across varying doses for glioma patients.
• These results may inform future treatment strategies in glioblastoma management but require external validation.